相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study
Walter Ageno et al.
LANCET HAEMATOLOGY (2016)
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
J. Stevanovic et al.
PLOS ONE (2016)
Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation: An Observational Study From a Cohort of Matched Users
Francois Laliberte et al.
CLINICAL THERAPEUTICS (2015)
Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
Merlijn W. J. van Leent et al.
PLOS ONE (2015)
Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
Alexander Mensch et al.
PHARMACOECONOMICS (2015)
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
Luke Bamber et al.
THROMBOSIS JOURNAL (2015)
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism
Bonno van Bellen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Stavros V. Konstantinides et al.
EUROPEAN HEART JOURNAL (2014)
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
Jelena Stevanovic et al.
PLOS ONE (2014)
Atrial Fibrillation and the Risk of Myocardial Infarction
Elsayed Z. Soliman et al.
JAMA INTERNAL MEDICINE (2014)
Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
Joris Kleintjens et al.
PHARMACOECONOMICS (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Martin H. Prins et al.
THROMBOSIS JOURNAL (2013)
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Yousif Ahmad et al.
HEART (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcome parameters for trials in atrial fibrillation: executive summary
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2007)
Pulmonary embolism and deep vein thrombosis
SZ Goldhaber et al.
CIRCULATION (2002)
The post-thrombotic syndrome: current knowledge, controversies, and directions for future research
SR Kahn et al.
BLOOD REVIEWS (2002)
分享论文
